IntoCell Inc

IntoCell Inc operates with a strong liquidity position, as evidenced by its current ratio of 9.71, indicating that current assets significantly exceed current liabilities. The company holds KRW 11,974,200,300 in cash and equivalents, which is a substantial portion of its total assets of KRW 41,253,688,510. However, the company's liquidity is offset by negative operating cash flow of KRW -8,626,402,890 and free cash flow of KRW -11,146,369,910, suggesting ongoing operational challenges. Profitability metrics are negative, with a return on equity of -42.84% and a return on assets of -25.7%. These figures indicate that the company is not generating returns for shareholders or effectively utilizing its assets. The debt-to-equity ratio of 0.41 suggests a relatively conservative capital structure, with long-term debt of KRW 10,214,182,580 compared to total equity of KRW 24,749,293,460. The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no material geographic diversification reported. This lack of diversification increases exposure to market-specific risks, particularly in the South Korean healthcare diagnostics market. IntoCell Inc reported revenue of KRW 2,299,122,480 for the latest period, but this is accompanied by a significant operating loss of KRW -10,582,217,360 and a net loss of KRW -10,603,468,810. The company has not provided specific guidance for future revenue growth, and its historical performance suggests a challenging path to profitability. Risk factors include the company's negative cash flows and operating losses, which could necessitate additional financing. However, the risk assessment indicates low dilution potential, with no immediate filing-based liquidity or dilution flags detected. The company's capital structure remains relatively stable, with no significant changes in shares outstanding between basic and diluted shares. Recent filings and transcripts have not disclosed any material events that would significantly alter the company's risk profile. The company continues to operate in a capital-intensive industry with high R&D costs, which is typical for biotechnology firms. No recent strategic shifts or major partnerships have been reported.